Daliresp
roflumilast
- Strength
- 500 ug/1
- Form
- Tablet
- Class
- Phosphodiesterase 4 Inhibitor
AstraZeneca Pharmaceuticals LP
Listed by Major Pharmaceuticals
| Dosage form | Tablet |
|---|---|
| Route | Oral |
| Drug class | Phosphodiesterase 4 Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 0904-7483 |
| FDA application | ANDA208256 |
| RxNorm concept | 1091839 |
| Package sizes listed | 2 |
| Marketed since | May 2024 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
roflumilast
AstraZeneca Pharmaceuticals LP
roflumilast
AstraZeneca Pharmaceuticals LP
Camber Pharmaceuticals, Inc.
Micro Labs Limited
Aurobindo Pharma Limited
Novadoz Pharmaceuticals LLC
MAJOR PHARMACEUTICALS
Camber Pharmaceuticals, Inc.
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.